JBIO Earnings & Financial Statements
Jade Biosciences, Inc.
$14.15
+$0.38(+2.76%)
30
Overall
60
Value
9
Tech
23
Quality
Market Cap
$875.74M
Volume
1.64M
52W Range
$8.36 - $28.00
Target Price
$49.89
JBIO earnings and financial statements: Jade Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
JBIO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$113.54M | -$74.60M | -$81.41M | -$53.24M | -$23.02M |
| EBITDA | -$135.11M | -$74.33M | -$78.43M | -$53.17M | -$22.87M |
| Net income | -$127.41M | -$69.63M | -$75.52M | -$51.51M | -$22.96M |
| EPS (diluted) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-65.45 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $349.78M | $72.80M | $127.42M | $135.30M | $175.36M |
| Total liabilities | $17.26M | $119.60M | $17.96M | $8.56M | $2.94M |
| Shareholders’ equity | $332.52M | -$46.80M | $109.46M | $126.74M | $172.42M |
| Cash and equivalents | $88.44M | $69.39M | $23.49M | $22.40M | $54.20M |
| Long-term debt | $724.0K | $107.60M | $255.0K | $705.0K | $382.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$94.69M | -$71.20M | -$56.78M | -$39.12M | -$27.40M |
| Capital expenditure | -$196.0K | - | - | -$195.0K | -$181.0K |
| Free cash flow | -$94.89M | -$71.20M | -$56.78M | -$39.32M | -$27.58M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JBIO | $14.15 | +2.8% | 1.64M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |